Lexeo Therapeutics (NASDAQ: LXEO) net income
Lexeo Therapeutics reported a net loss of $100.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $98.3m. Earnings per share were −$1.86.
Lexeo Therapeutics's best year of the last 4 was fiscal 2022. It reported a loss in 4 of those 4 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$100.0m | — | — | −$1.86 |
| 2024 | −$98.3m | — | — | −$3.09 |
| 2023 | −$66.4m | — | — | −$12.40 |
| 2022 | −$59.3m | — | −9,063.8% | −$36.36 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Lexeo Therapeutics net income compared with its sector
By net income for its latest fiscal year, Lexeo Therapeutics ranks 333rd of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 331st | AMN Healthcare Services | −$95.7m | −3.5% |
| 332nd | Prelude Therapeutics | −$99.5m | −819.6% |
| 333rd | Lexeo Therapeutics | −$100.0m | — |
| 334th | Tango Therapeutics | −$101.6m | −162.9% |
| 335th | ALX Oncology | −$101.7m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Lexeo Therapeutics
- How much did Lexeo Therapeutics earn in fiscal 2025?
- Lexeo Therapeutics reported a net loss of $100.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $98.3m.
- What are the earnings per share of Lexeo Therapeutics?
- They were −$1.86 in fiscal 2025, compared with −$3.09 in fiscal 2024.
- Where does Lexeo Therapeutics rank in its sector by net income?
- It ranks 333rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Lexeo Therapeutics come from?
- From the annual report (Form 10-K) that Lexeo Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Lexeo Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on Lexeo Therapeutics: the Lexeo Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.